media – Page 2 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Refusal to adjust prices, a number of pharmaceutical companies “out”

On November 18, at the 44th China Pharmaceutical Industry Development Summit Forum, Geng Hongwu, executive deputy director of the Medical and Health Research Center of the Tsinghua University Association of Senior Scientists, pointed out that the basic ideas of my country’s medical insurance drug price management at this stage mainly include: management scope, quality-price matching, reasonable price difference, medical insurance guidance, strict supervision, etc. “Exerting the effectiveness of drug price governance” is one of the key tasks of the National Medical Insurance Administration this year. That is, to promote special governance of online drug prices, explore new mechanisms for drug price formation, and increase the disclosure of price procurement credit evaluation. Recently, the Shanxi Provincial Drug and Equipment Centralized Bidding and Procurement Center issued the “Notice on the Adjustment and Disposal of the Centralized Procurement Prices of Amoxicillin and Other Drugs of the Guangdong Alliance”. The relevant companies of 20 ...
- Source: drugdu
- 30
- November 20, 2024
Celltrion expands European market, acquires iQone Healthcare for 30 billion

On Friday, South Korean biosimilar giant Celltrion said it had completed the acquisition of iQone Healthcare Switzerland for approximately 30 billion won (about 155 million yuan) as part of its European expansion strategy. After the acquisition, iQone Healthcare Switzerland will become a wholly-owned subsidiary of Celltrion Healthcare Hungary Kft. The transaction will also provide Celltrion with the opportunity to obtain authorizations, further enhancing its pipeline of innovative therapies. In 2022, iQone’s annual revenue was 18.9 billion won (about 18.9 million US dollars), and sales increased by 57% to 29.6 billion won in 2023. Celltrion said the acquisition will further accelerate the expansion of its prescription drug business in Switzerland. According to IQVIA data, sales performance in the country remains strong, with the Ramsima series (IV and SC) accounting for 61% of the market share in the second quarter of this year. The company noted that its follow-up products are expected ...
- Source: drugdu
- 31
- November 20, 2024
Pumis announces equity acquisition agreement with BioNTech

According to the terms of the agreement, BioNTech will acquire 100% of Pumis’ issued share capital for a prepayment of $800 million (approximately RMB 5.781 billion) (subject to customary adjustment of the acquisition price), primarily in cash and a portion of American Depositary Shares (ADS). In addition, BioNTech will pay an additional milestone payment of up to $150 million (approximately RMB 1.084 billion) when Pumis meets the milestone conditions agreed upon by both parties. The transaction is expected to be completed in the first quarter of 2025, subject to customary delivery conditions and regulatory approvals. After the completion of this transaction, BioNTech will acquire full rights to the Pumis candidate drug pipeline and its bispecific antibody drug development platform, further expanding its business scope in China; Pumis Zhuhai will serve as the BioNTech China R&D center to conduct related R&D research; The Pumis Nantong production base, which meets international standards, ...
- Source: drugdu
- 42
- November 19, 2024
WuXi AppTec’s Couvet Site Receives EcoVadis 2024 Silver Medal Rating

Couvet, Switzerland – November 14, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is proud to announce that its facility in Couvet, Switzerland, has received a silver medal in the 2024 business sustainability ratings by EcoVadis, a leading business sustainability rating provider. This recognition highlights WuXi AppTec’s steadfast commitment to integrating Environmental, Social, and Governance (ESG) priorities into its strategy and operations. EcoVadis provides benchmarks for rated companies in their industry to drive global supply chain sustainability and encourage industry-wide competence to achieve better global practice and continuous improvement. The ratings assess corporate performance across four core areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. With an impressive score, WuXi AppTec’s Couvet site ranks in the top 9% of all rated companies, showcasing its commitment to sustainable business practices. ...
- Source: drugdu
- 38
- November 19, 2024
26.7 billion! Boston Scientific completes blockbuster acquisition

On November 15, local time, Boston Scientific announced the completion of its acquisition of medical technology company Axonics, Inc. The transaction was priced at $71 per share, with an equity value of $3.7 billion (equivalent to approximately RMB 26.76 billion). Boston Scientific expects that the transaction will have little impact on adjusted earnings per share in 2024 and 2025, and will increase thereafter. Axonics focuses on the development and commercialization of differentiated devices for the treatment of urinary and intestinal dysfunction. Its core products include sacral nerve modulation systems and urethral swelling hydrogels. Axonics is an important competitor of Medtronic in the field of sacral nerve modulation. This field was previously an absolute dominance of Medtronic. After the approval of Axonics products, it gradually expanded its market territory. Data shows that the company has a 27% market share in the sacral nerve modulation market. Axonics ranked second in the list ...
- Source: drugdu
- 39
- November 19, 2024
The National Health Commission expressed its support for marketing and academic exchanges in compliance with regulations

Recently, the National Health Commission organized a symposium with 24 pharmaceutical/medical device companies, including domestic/multinational companies, state-owned/private companies, and traditional Chinese medicine/chemical medicine/medical device companies. According to the meeting arrangements circulated in the industry, the symposium conducted research and discussions on six aspects (see the following figure for details), including “supporting medical staff to participate in academic conferences of Chinese and foreign pharmaceutical companies in compliance with regulations and to receive lecture fees in compliance with regulations.” At the meeting, the National Health Commission also made it clear that “support and guide the standardized development of academic exchanges and cooperation, and conduct marketing in compliance with regulations.” In fact, this is not the first time that the state has expressed its support for the compliance of pharmaceutical academic conferences and marketing. In the second half of 2023, various departments launched a special rectification of unhealthy trends in the pharmaceutical field, ...
- Source: drugdu
- 41
- November 19, 2024
A “dark horse” has emerged in breast cancer treatment

The birth of blockbuster drugs in the field of breast cancer is not new. After all, there is fertile soil for the birth of big drugs here. The most core factor is the extremely large patient population. Breast cancer is one of the most common cancers and one of the leading causes of cancer-related deaths worldwide. In 2020, more than 2 million patients were diagnosed with breast cancer. In the United States, more than 290,000 patients are expected to be diagnosed in 2023. And the proportion of important subtypes is not low. For example, HR+ breast cancer is the most common breast cancer subtype, and more than 65% of breast cancer tumors are considered to be HR+/HER2 low expression or negative. Therefore, a strong demand for drugs has been created. The growth of HR+ breast cancer cells is usually driven by estrogen receptors (ER). Endocrine therapy for ER-driven diseases is ...
- Source: drugdu
- 33
- November 19, 2024
Haoyuan Pharmaceutical’s stock price rose by more than 150%

The cold winter of CXO has lasted for three full years since the second half of 2021. From industry leaders to emerging pharmaceutical companies, everyone has felt the chill. However, since the second half of 2024, the entire industry has shown some signs of recovery. Against the backdrop of interest rate cuts in Europe and the United States, the situation in the pharmaceutical investment and financing market has reversed, orders from many listed companies have begun to grow, and the industry turning point is about to come. Haoyuan Pharmaceutical is one of the first CXO companies to feel the warmth. Since the end of August, the stock price has risen from a low of 18.49 yuan/share to a high of 46.52 yuan/share, an increase of more than 150%. Haoyuan Pharmaceutical stock price trend Image source: Oriental Fortune What is the secret of Haoyuan Pharmaceutical behind the fluctuations in stock prices? ...
- Source: drugdu
- 28
- November 19, 2024
MD&M West

Organiser：Informa Markets Time：February 4-6, 2025 Address：800 W. Katella Ave., Anaheim, CA 92802, USA Exhibition hall：Anaheim Convention Center Product range: Medical Supplies: Anesthesiology & Respiratory Medications, Home Care Products, Cardiovascular Supplies, Orthopedic Surgical Instruments, Radiology & Medical Imaging, Emergency & Trauma Care, Surgical Instruments, Sports Medicine & Rehabilitation Therapy, In Vitro Diagnostic Equipment, and General Hospital Supplies & Equipment Medical Materials & Components: New Materials, 3D Printing, Robotics & Automation, Silicones, Mobile Power Solutions, Essential Considerations for Avoiding Medical Device Battery Failures, Innovative Medical Devices, Metal 3D Printing, Intelligent Layering, Integrated Product Design & Development Services Medical Devices: Medical Technology Equipment, Laboratory Instrumentation, Medical Electronic Equipment, Medical Diagnostic Equipment, Ophthalmic Equipment & Protective Products, Surgical Instruments, Emergency Response Equipment, Hospital, Dental & Medical Equipment, Dental Service Equipment & Disposable Medical Products, Disposable Medical Products for Hospitals & Homes, Hospital Dentistry, Medical Data Processing Systems, Dental Plastic Surgery, Rehabilitation Equipment, etc. ...
- Source: drugdu
- 42
- November 19, 2024
【EXPERT Q&A】What are the requirements for naming in vitro diagnostic reagents?

Drugdu.com expert’s response: The naming of in vitro diagnostic reagents must follow a series of clear requirements to ensure the standardization, accuracy, and ease of understanding of the names. These requirements mainly include the following points: Ⅰ. Naming Structure The product name of in vitro diagnostic reagents typically consists of three parts: Name of the Substance Being Tested: This is the target substance that the reagent detects, and the name should accurately reflect the characteristics of the substance being tested. Purpose: Describes the purpose of the reagent, such as “assay kit,” “quality control material,” etc. This part helps users understand the specific application of the reagent. Method or Principle: Explains the method or principle of the reagent’s detection, such as “magnetic bead-based chemiluminescent immunoassay,” “fluorescent PCR method,” “fluorescent in situ hybridization,” etc. This information is usually listed in parentheses to provide additional technical details. Ⅱ. Specific Naming Rules Quantitative vs. Qualitative ...
- Source: drugdu
- 34
- November 18, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.